The single human erythropoietin gene, located on chromosome 7, consists of 5 exons spanning 3 kb of genomic DNA. In human, rodents and sheep, erythropoietin is produced by the fetal/neonatal liver, followed by a gradual transition to primary production by the adult kidney. 1.6 and 2.0 kb RNA species have been identified in preparations from human liver. Comparison of the human and murine erythropoietin gene sequences has revealed a striking degree of homology within amino-acid coding sequences. In addition, specific 5' - and 3' -flanking sequences as well as sequences within the first intron of the gene are highly conserved, suggesting that these sequences may have functional significance. The purpose of this study is to utilize the newly-developed technique of pronuclear microinjection to analyze the DNA sequences involved in the tissue and developmental-stage specific regulation of the human erythropoietin gene. We will first test the hypothesis that transgenic mice harboring a 4 kb human genomic DNA fragment encompassing the erythropoietin gene will coordinately express the endogenous murine erythropoietin gene and the transgene. Important parameters that will be studied include the ability of the transgene to undergo normal regulation as measured by developmental-stage and tissue-specific expression and response to inductive stimuli such as hypoxia. The second stage of the study will involved the identification of the DNA sequences involved in the regulation of erythropoietin gene expression. Deletion mutants lacking specific sequences which are conserved between the murine and human erythropoietin genes will be constructed and introduced into transgenic mice. Expression of these altered transgenes will be compared to that of the intact transgene in terms of tissue and developmental specificity. The results of these studies should have significance with respect to our general understanding of the control of gene expression, as well as more specific questions regarding the hormonal regulation of hematopoiesis, during development.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK039869-02
Application #
3239863
Study Section
Diabetes and Digestive and Kidney Diseases Special Grants Review Committee (DDK)
Project Start
1987-09-30
Project End
1990-08-31
Budget Start
1988-09-01
Budget End
1989-08-31
Support Year
2
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Semenza, Gregg L (2003) Angiogenesis in ischemic and neoplastic disorders. Annu Rev Med 54:17-28
Cai, Zheqing; Manalo, Dominador J; Wei, Guo et al. (2003) Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 108:79-85
Kelly, Brian D; Hackett, Sean F; Hirota, Kiichi et al. (2003) Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res 93:1074-81
Fukuda, Ryo; Hirota, Kiichi; Fan, Fan et al. (2002) Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 277:38205-11
Semenza, Gregg L (2002) Physiology meets biophysics: visualizing the interaction of hypoxia-inducible factor 1 alpha with p300 and CBP. Proc Natl Acad Sci U S A 99:11570-2
Shimoda, L A; Manalo, D J; Sham, J S et al. (2001) Partial HIF-1alpha deficiency impairs pulmonary arterial myocyte electrophysiological responses to hypoxia. Am J Physiol Lung Cell Mol Physiol 281:L202-8
Hirota, K; Semenza, G L (2001) Rac1 activity is required for the activation of hypoxia-inducible factor 1. J Biol Chem 276:21166-72
Mahon, P C; Hirota, K; Semenza, G L (2001) FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 15:2675-86
Semenza, G L (2001) Hypoxia-inducible factor 1: control of oxygen homeostasis in health and disease. Pediatr Res 49:614-7
Laughner, E; Taghavi, P; Chiles, K et al. (2001) HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21:3995-4004

Showing the most recent 10 out of 48 publications